2025 Awardee - Translational Research Edition
Discovery of treatment failure mechanisms in CAR T cell therapy through proteomic analysis
Learn more
seer insights program
Advancing translational and development-stage proteomics
Seer Insights Program supports researchers and development teams seeking deeper biological insight through unbiased proteomics. This initiative includes two distinct pathways designed to support both translational discovery and development-stage programs.
Choose the pathway that best fits your research or development needs.
Choose your program pathway
Academic Translational Research Track
For academic investigators advancing translational proteomics research with clear relevance to human health.
This track supports studies that bridge biological discovery and clinical relevance by generating deep proteomic insights that enable biomarker discovery, disease understanding, and translational application.
Selected investigators receive:
- End-to-end access to Seer’s Proteograph® workflow
- High-depth mass spectrometry analysis
- Dedicated scientific collaboration with Seer experts
- Structured bioinformatics support to enable data interpretation
Ideal for:
- Identifying protein biomarkers associated with disease or clinical outcomes
- Investigating disease biology using patient-derived or translational cohorts
- Generating datasets to support future translational or clinical studies
Selected projects will be supported through Seer’s Technology Access Center (STAC), with defined study scope including sample processing, proteomic analysis, and collaborative data review.
Biopharma Development Access Program
For biotechnology and pharmaceutical teams seeking proteomic insight to inform development-stage programs particularly those without established in-house mass spectrometry proteomics capabilities.
This selective program is designed to support development-stage programs by generating deep, unbiased proteomic insights that inform critical pipeline decisions, including target validation, mechanism of action, resistance biology, and patient stratification.
Participants receive:
- Dedicated Seer scientific partnership
- Accelerated review timeline
- Confidential participation option
- Ownership of data and resulting intellectual property
Ideal for:
- Investigating protein pathways in preclinical models to support target validation or IND-enabling biology
- Comparing proteomic profiles between treatment responders and non-responders
- Exploring circulating protein signatures linked to clinical outcomes
Selected teams receive access to Seer’s Proteograph® workflow through the Seer Technology Access Center (STAC), enabling deep proteomic analysis to inform development decisions.
For academic investigators advancing translational proteomics research with clear relevance to human health.
This track supports studies that bridge biological discovery and clinical relevance by generating deep proteomic insights that enable biomarker discovery, disease understanding, and translational application.
Selected investigators receive:
- End-to-end access to Seer’s Proteograph® workflow
- High-depth mass spectrometry analysis
- Dedicated scientific collaboration with Seer experts
- Structured bioinformatics support to enable data interpretation
Ideal for:
- Identifying protein biomarkers associated with disease or clinical outcomes
- Investigating disease biology using patient-derived or translational cohorts
- Generating datasets to support future translational or clinical studies
Selected projects will be supported through Seer’s Technology Access Center (STAC), with defined study scope including sample processing, proteomic analysis, and collaborative data review.
For biotechnology and pharmaceutical teams seeking proteomic insight to inform development-stage programs particularly those without established in-house mass spectrometry proteomics capabilities.
This selective program is designed to support development-stage programs by generating deep, unbiased proteomic insights that inform critical pipeline decisions, including target validation, mechanism of action, resistance biology, and patient stratification.
Participants receive:
- Dedicated Seer scientific partnership
- Accelerated review timeline
- Confidential participation option
- Ownership of data and resulting intellectual property
Ideal for:
- Investigating protein pathways in preclinical models to support target validation or IND-enabling biology
- Comparing proteomic profiles between treatment responders and non-responders
- Exploring circulating protein signatures linked to clinical outcomes
Selected teams receive access to Seer’s Proteograph® workflow through the Seer Technology Access Center (STAC), enabling deep proteomic analysis to inform development decisions.
About Seer Insights
Seer Insights is designed to accelerate the application of deep, unbiased proteomics across discovery and development.
Through access to Seer’s Proteograph® workflow and the Seer Technology Access Center (STAC), participants can generate high-depth proteomic datasets that reveal biology inaccessible through conventional approaches.
Participants may receive support including:
- Deep, unbiased proteomic profiling through the Proteograph® workflow
- High-resolution mass spectrometry analysis at scale
- Collaborative data interpretation with Seer scientists
- Structured support to translate proteomic data into biological insight
2026 Program Timeline
- April 19, 2026 Program launch and submission window opens
- June 12, 2026 Submission deadline
- End of June 2026 Program selections announced
Seer Insights Program: Frequently Asked Questions
What is the Seer Insights Program?
Seer Insights is a two-track initiative designed to advance proteomics from discovery to development. The program includes:
- The Translational Research Track, supporting academic translational investigators bridging biological discovery to clinical, therapeutic, or applied health relevance.
- The Biopharma Development Access Program, supporting biotech and pharmaceutical teams generating decision-enabling proteomics data for development-stage programs.
Both tracks provide access to Seer’s Proteograph® Product Suite through the Seer Technology Access Center (STAC), along with mass spectrometry and bioinformatics support.
Do both tracks use the same application process?
No. Each track has its own submission process designed for the needs of the respective audience.
Academic researchers submit a research proposal through an online application form.
Biopharma teams submit a short concept describing how proteomic analysis could inform a development-stage program.
What sample types are compatible?
Projects must align with the capabilities of Seer’s Proteograph® technology. Compatible sample types include plasma, serum, and cerebrospinal fluid (CSF). Applicants are encouraged to review the Proteograph Product Suite page to confirm technical alignment prior to submission. Detailed eligibility and submission information is available on each program track page.
Who is this program intended for?
The Seer Insights program is designed for researchers and development teams who do not have established in-house mass spectrometry-based proteomics capabilities and are seeking to incorporate deep proteomic analysis into their work.
Studies Enabled through Seer Insights
The Seer Insights initiative has supported research across a range of disease areas, enabling investigators to uncover novel biology through deep proteomic analysis.
Explore selected research highlights generated through Seer Insights programs.
Subscribe for Seer Insights Program Updates
Sign-up to get updates and receive the latest news on products and events from Seer.